Drug intelligence / Profile preview

MSM-735

Development stage: Preclinical
Lead developer: MSM Protein Technologies
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MSM-735 is a monoclonal antibody currently in preclinical development by MSM Medical. It is designed to target an undisclosed membrane protein or G protein-coupled receptor (GPCR). The therapeutic candidate is being investigated for a broad range of indications, including hematological malignancies, metastatic solid tumors (specifically pancreatic cancer, gastric cancer, and melanoma), idiopathic pulmonary fibrosis (IPF), and multiple sclerosis (MS). According to the company's pipeline, the program is in the lead optimization stage for IPF and MS, while the oncology indications are in the preclinical stage.

Targets

CCR7 (C-C Motif Chemokine Receptor 7)

Beyond the preview

Go deeper on MSM-735.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSM-735.

Explore the full profile